Glycitein for COVID-19

c19early.org

COVID-19 Treatment Clinical Evidence

COVID-19 involves the interplay of 500+ viral and host proteins and factors, providing many therapeutic targets. c19early analyzes 6,000+ studies for 220+ treatments—over 17 million hours of research. Only three high-profit early treatments are approved in the US. In reality, many treatments reduce risk, with 26 low-cost treatments approved across 163 countries.

Naso/oropharyngeal treatment Effective Treatment directly to the primary source of initial infection.
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.

Glycitein may be beneficial for COVID-19 according to the studies below. COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 12,000+ potential treatments. c19early.org analyzes 220+ treatments. We have not reviewed glycitein in detail.

Studies suggesting benefit with glycitein

Huang et al., Magnetic Bead‐Based Ligand Fishing Identifies SARS‐CoV‐2 Main Protease Inhibitors From Reynoutria japonica, Chemistry & Biodiversity, doi:10.1002/cbdv.71722

ABSTRACT Traditional Chinese medicines (TCMs) are rich sources of structurally diverse bioactive compounds, yet rapid identification of protease inhibitors from complex botanical matrices remains challenging. Here, a magnetic bead‐based affinity‐fishing platform coupled with UPLC‐Q‐Exactive‐Orbitrap‐MS/MS was applied to identify SARS‐CoV‐2 main protease (M pro ) inhibitors from Reynoutria japonica . The crude ethanolic extract inhibited M pro with an IC 50 of 44.92 ± 2.31 µg/mL. M pro ‐functionalized magnetic beads enriched eight constituents, which were identified by high‐resolution mass spectrometry and evaluated using a FRET‐based inhibition assay. Six compounds showed concentration‐dependent activity, with resveratrol being the most potent (IC 50 = 34.01 ± 1.67 µmol/L), followed by glycitein, genistein, emodin, apigenin‐7‐ O ‐glucoside, and biochanin A. HPLC‐DAD further quantified the principal active constituents. Molecular docking suggested interactions with residues in the Mpro substrate‐binding pocket, while network pharmacology predicted associations with host‐related targets involving IL6, TNF, and AKT1. Overall, this workflow enables efficient enrichment, structural identification, and functional prioritization of M pro ‐inhibitory constituents from complex botanical extracts, providing a practical strategy for target‐directed natural product discovery.

Günther et al., X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease, Science, doi:10.1126/science.abf7945

A large-scale screen to target SARS-CoV-2 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome is initially expressed as two large polyproteins. Its main protease, M pro , is essential to yield functional viral proteins, making it a key drug target. Günther et al. used x-ray crystallography to screen more than 5000 compounds that are either approved drugs or drugs in clinical trials. The screen identified 37 compounds that bind to M pro . High-resolution structures showed that most compounds bind at the active site but also revealed two allosteric sites where binding of a drug causes conformational changes that affect the active site. In cell-based assays, seven compounds had antiviral activity without toxicity. The most potent, calpeptin, binds covalently in the active site, whereas the second most potent, pelitinib, binds at an allosteric site. Science , this issue p. 642